Sharing R&D Risk in Healthcare via FDA Hedges

Bank lines of credit as contingent liquidity: Covenant violations and their implications

Adam Jørring, Andrew W Lo, Tomas Philipson, Manita Singh and Richard T Thakor

The Review of Corporate Finance Studies, 2022, vol. 11, issue 4, 880-922

Abstract: Biomedical innovation suffers from a “funding gap” between the needs of drug development firms and the availability of funds. The requirement of large investments for drug development projects and the high pipeline risk associated with FDA approval causes this funding gap in part. In this paper, we propose a new financial instrument—the “FDA hedge”—that pays off upon FDA approval failure. We develop a theory to show that the FDA hedge can help eliminate the funding gap. Using novel project-level data, we establish empirically that FDA hedge risk is idiosyncratic, and show how better sharing this risk can spur welfare-enhancing R&D. (JEL G11, G13, G22, I11, L65, O32Authors have furnished an Internet Appendix, which is available on the Oxford University Press Web site next to the link to the final published paper online.

Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://hdl.handle.net/10.1093/rcfs/cfab024 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
Working Paper: Sharing R&D Risk in Healthcare via FDA Hedges (2017)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:rcorpf:v:11:y:2022:i:4:p:880-922.

Access Statistics for this article

The Review of Corporate Finance Studies is currently edited by Andrew Ellul

More articles in The Review of Corporate Finance Studies from Society for Financial Studies
Bibliographic data for series maintained by Oxford University Press ().